BAUSCH+LOMB

See better. Live better.

United States

Newsroom Careers Investor Relations
Contact Us

For Eye Care Professionals

Text size A- A+

Our Products

Vision and Age

Your Eye Concerns

Our Company

Search...

Home >...>Rx Pharmaceutical >PROLENSA (bromfenac ophthalmic solution) 0.07% >Co-Pay Assistance

PROLENSA (bromfenac ophthalmic solution) 0.07%

PROLENSA HOME

PROLENSA® (bromfenac ophthalmic solution) 0.07%



Commercially Insured/Uninsured Patients and Medicare Part D Insured Patients

Bausch + Lomb is committed to providing programs that help patients get the medications they need by offering co-pay assistance for treatment costs.



Each of these programs has different terms, with a minimum co-pay and a maximum benefit.

Commercially Insured/Uninsured Patients

Eligible patients can receive a payment assistance card, limiting their prescription co-pay cost.

DOWNLOAD PDF



Medicare Part D Insured Patients

Patients may opt-in to the program to pay no more than \$60. For more information, click here.

DOWNLOAD PDF



INDICATION FOR PROLENSA (bromfenac ophthalmic solution) 0.07%

PROLENSA (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti-inflammatory drug (NSAID) indicated to treat inflammation and reduce eye pain in



IPR2015-01099 IPR2015-01097 IPR2015-01100

Lupin EX1155 Page 1

Find authenticated court documents without watermarks at docketalarm.com. IPR2015-01105

PROLENSA contains sodium sulfite, a substance that may cause allergic reactions, some severe, in certain people. In addition, tell your doctor if you have had an allergic reaction to any other medications.

Slow or delayed healing may occur while using non-steroidal anti-inflammatory drugs (NSAIDs) such as PROLENSA.

Use of NSAIDs in the eye may result in certain serious eye conditions that can be sight threatening. Tell your doctor immediately about any side effect that you may have.

Replace bottle cap after using and do not touch dropper tip to any surface in order to avoid contamination of the bottle.

Remove contact lenses prior to using *PROLENSA*. The preservative in *PROLENSA*, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of *PROLENSA*.

If more than one eye medicine is being used, use the eye medicines at least 5 minutes apart.

The most common side effects (seen in 3%-8% of patients) were inflammation of the eye, foreign body sensation, eye pain, light sensitivity, and blurred vision.

Please click here for Prescribing Information about PROLENSA.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

US/PRA/15/0042(1)

Vision and Eye Health	Products	Customer Support	Legal	Newsroom
Vision and Age	Contact Lenses	Contact Us	Legal Notice	Careers
Eye Infections & Irritations	Contact Lens Care	Customer policies and forms	Privacy Policy	Investor Relations
Diseases and Disorders	Dry Eye Products	Rebate Center	Safety Data Sheets (SDS)	Grants & Contributions
Find a Doctor	Allergy/Redness Relief	Worldwide Locations	i !	
PDFEye Exam Check List	Rx Pharmaceutical			
	Eye Vitamins			
	Surgical Products			
	Vision Accessories			
		1	1	1

© 2016 Bausch & Lomb Incorporated.

All information and materials on this site pertain to the U.S. only, unless otherwise indicated.

